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We have employed standard tritiodeiodination for radiolabelling peptides of different biological 
importance. Gliadin-19 and Gliadin-33 with a molecular weight (as the trifluoroacetate salt) of 
2591 and 4026 respectively are natural occurring peptide fragments of gluten proteins. PACAP-
38 with a molecular weight of 6271 is biologically important due to a putative mechanism for 
inducing headache
1
.  
 
The tritium labelling reactions have been performed using identical reaction conditions
2
 but with 
different amounts of precursor peptide, we here compare the results from these reactions. The 
reactions were performed on a tritium manifold system (RC TRITEC, Teufen, Switzerland). In a 
small round bottomed flask synthetic precursor peptide as TFA salt (0.6 – 2.2 µmol) was loaded 
together with catalyst (10% Pd/C, 4-5 mg) and suspended in DMF (1 ml). After the employment 
of 8-10 Ci of tritium gas for 2 hours, the peptide was purified and analysed. The peptide recovery 
(PR%), specific activity (SA) and radiochemical yield (RCY) were then determined. Results 
from 5 independent reactions are summarised in the table below.  
 
  Reaction Conditions Crude Purified 
Peptide 
MW 
(TFA) 
Peptide 
[mg] 
µmol 
Pd 
[mg] 
T2  
[Ci] 
RCY 
[mCi] 
RCP% PR% 
SA 
[Ci/mmol] 
RCY 
[mCi] 
Gliadin-19 
2591 
4.1 1.582 5.1 10.0 50.9 100 66% 28.8 30.0 
Gliadin-19 5.5 2.123 5.3 10.0 53.5 100 63% 29.7 39.6 
Gliadin-33 
4026 
6.2 1.540 5.1 10.3 33.3 81 84% 15.9 20.5 
Gliadin-33 9.2 2.285 5.3 10.0 31.8 61 68% 13.7 21.4 
PACAP-38 6271 4.0 0.638 4.1 8.25 22.6 85 60% 25.1 9.7 
Table: Result from 5 tritiation reactions. MW is protonated trifluoroacetate salt of precursor peptide, tritiation of Gliadine-19 showed only one peak in 
the radiochromatogram, thus the RCP of 100%. 
 
Great success using these reaction conditions and methodology was found, both for the 
radiochemical yield and the peptide recovery. Double iodinated precursors yielded products with 
approx. one tritium atom per molecule.  
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